The Investor
13 Mar 2026, 19:36
Johnson & Johnson reported promising early clinical results for its investigational bladder cancer therapy Erda-iDRS, a drug-releasing system delivering erdafitinib directly into the bladder.
In a Phase 1 study involving patients with intermediate-risk non-muscle-invasive bladder cancer, the treatment achieved an 89% complete response rate, with many responses lasting up to 18 months. The therapy also showed encouraging recurrence-free outcomes in high-risk patients and demonstrated a generally tolerable safety profile.
The results, presented at the European Association of Urology 2026 meeting, support further development of the targeted therapy, with ongoing Phase 2 and Phase 3 trials evaluating its potential as a treatment option for early-stage bladder cancer.
PRNewswire
In a Phase 1 study involving patients with intermediate-risk non-muscle-invasive bladder cancer, the treatment achieved an 89% complete response rate, with many responses lasting up to 18 months. The therapy also showed encouraging recurrence-free outcomes in high-risk patients and demonstrated a generally tolerable safety profile.
The results, presented at the European Association of Urology 2026 meeting, support further development of the targeted therapy, with ongoing Phase 2 and Phase 3 trials evaluating its potential as a treatment option for early-stage bladder cancer.
PRNewswire